FDA Approves Onpattro, a Novel RNAi Therapeutic to Treat Polyneuropathy in Adults

 FDA Approves Onpattro, a Novel RNAi Therapeutic to Treat Polyneuropathy in Adults

FDA Approves Onpattro, a Novel RNAi Therapeutic to Treat Polyneuropathy in Adults

Shots:
  • Alnylam’s siRNA molecule Onpattro receives FDA approval for fatal genetic disorder polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR)
  •  Approval is based on results from Ph III APOLLO study involving 19 countries with the ratio of 2:1 of Onpattro vs Placebo once Q3W for 18mos showing improved QoL
  • Alnylam is expected to receive CHMP opinion by Sep’18, with expected regulatory filings in other markets, including Japan in H2’18

Click here to read full press release/ article | Ref: US FDA | Image:  Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post